Northwest Biotherapeutics, Inc. (BST:NBYB)

Germany flag Germany · Delayed Price · Currency is EUR
0.2200
+0.0100 (4.76%)
At close: Jul 3, 2025
-40.22%
Market Cap 311.78M
Revenue (ttm) 1.36M
Net Income (ttm) -79.49M
Shares Out n/a
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,000
Average Volume 11,991
Open 0.2000
Previous Close 0.2100
Day's Range 0.2000 - 0.2200
52-Week Range 0.1730 - 0.4500
Beta n/a
RSI 48.94
Earnings Date Aug 11, 2025

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types o... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1996
Employees 25
Stock Exchange Stuttgart Stock Exchange
Ticker Symbol NBYB
Full Company Profile

Financial Performance

In 2024, Northwest Biotherapeutics's revenue was $1.38 million, a decrease of -28.47% compared to the previous year's $1.93 million. Losses were -$85.19 million, 32.3% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.